ProKidney, Calidi Biotherapeutics, and Basel Medical Group are the three Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are shares of small companies that trade at relatively low prices—typically under $5 per share—and are often found on over-the-counter (OTC) markets rather than major exchanges. Because they tend to have low liquidity, limited financial disclosure requirements and wide price swings, penny stocks carry a higher risk and greater potential for both large gains and significant losses. These companies had the highest dollar trading volume of any Penny stocks within the last several days.
ProKidney (PROK)
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
NASDAQ PROK traded up $0.65 during trading hours on Wednesday, hitting $4.38. The company's stock had a trading volume of 202,189,667 shares, compared to its average volume of 2,884,192. ProKidney has a 52 week low of $0.46 and a 52 week high of $7.09. The company's 50-day simple moving average is $0.82 and its two-hundred day simple moving average is $1.11. The company has a market capitalization of $1.28 billion, a PE ratio of -7.30 and a beta of 1.26.
Read Our Latest Research Report on PROK
Calidi Biotherapeutics (CLDI)
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.
Shares of NYSE:CLDI traded up $0.42 during mid-day trading on Wednesday, reaching $0.75. The company had a trading volume of 601,593,665 shares, compared to its average volume of 6,105,310. The company's 50-day moving average price is $0.36 and its 200-day moving average price is $0.69. Calidi Biotherapeutics has a one year low of $0.20 and a one year high of $3.89.
Read Our Latest Research Report on CLDI
Basel Medical Group (BMGL)
Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement.
Basel Medical Group stock traded up $1.50 during mid-day trading on Wednesday, reaching $3.32. The company's stock had a trading volume of 80,263,273 shares, compared to its average volume of 4,730,099. The stock has a fifty day moving average of $2.94. Basel Medical Group has a 12-month low of $0.91 and a 12-month high of $9.40.
Read Our Latest Research Report on BMGL
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ProKidney, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProKidney wasn't on the list.
While ProKidney currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
